文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

既往耐药突变者换用B/F/TAF的病毒学结局:意大利ARCA队列BIC-BARRIER研究

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究基于意大利ARCA队列1414例经治HIV-1感染者,估算换用B/F/TAF时NRTI和INSTI耐药突变流行率并分析其与病毒反弹的关系。结果显示NRTI耐药突变常见(25%)但不影响病毒学应答,而既往INSTI治疗失败史和主要INSTI耐药突变与病毒反弹风险升高相关。

要点

  • 换用B/F/TAF时NRTI耐药突变常见(25%),但不增加病毒反弹风险。
  • 主要INSTI耐药突变罕见(0.6%),但与病毒反弹风险升高相关(aRH 4.21)。
  • 既往INSTI治疗失败史亦为病毒反弹的独立危险因素(aRH 2.68)。

核心结论

  • 在换用B/F/TAF的经治HIV感染者中,NRTI耐药突变虽常见,但B/F/TAF仍能维持病毒抑制。
  • 既往INSTI方案治疗失败史和主要INSTI耐药突变是换用B/F/TAF后病毒反弹的危险因素。

研究设计与样本

  • 基于意大利ARCA队列的回顾性分析,纳入1414例换用B/F/TAF的经治HIV-1感染者,其中973例(69%)纳入病毒反弹分析。
  • 采用二项分布估算耐药流行率并报告95%CI,采用标准生存分析评估耐药与确认病毒反弹(连续两次>50 copies/mL)的关联。

主要发现

  • 总体中位年龄53岁(IQR 44-59),27%为女性。
  • 主要NRTI耐药突变检出率为25%(95%CI: 22.5, 27.1)。
  • 影响比克替拉韦的主要INSTI耐药突变罕见,为0.6%(95%CI: 0.2, 1.4)。
  • 36个月时总体病毒反弹率为5.3%(95%CI: 3.7-6.9%)。
  • 控制混杂因素后,NRTI耐药与病毒反弹无关,而既往INSTI治疗失败史(aRH 2.68, 95%CI: 1.40, 5.12)和主要INSTI耐药突变(aRH 4.21, 95%CI: 1.18, 15.02)与病毒反弹相关。

临床怎么用

  • 对于既往无INSTI治疗失败且无主要INSTI耐药突变的经治感染者,即使存在NRTI耐药突变,换用B/F/TAF仍为有效选择。
  • 换用B/F/TAF前应评估INSTI治疗史和耐药突变,尤其关注既往INSTI方案失败者,此类患者病毒反弹风险较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the prevalence of NRTI and integrase strand transfer inhibitor (INSTI), drug resistance mutations (DRMs) in antiretroviral therapy (ART)-experienced people with HIV-1 (PWH) switched to bictegravir/emtricitabine/tenofovir alafenamide fumarate (B/F/TAF) and among those with HIV-RNA ≤50 copies/mL to assess the association with risk of viral rebound (VR). METHODS: Data from the ARCA cohort were used to estimate resistance prevalence assuming a binomial distribution; 95% confidence intervals (CIs) were reported. Standard survival analysis with time-fixed covariate measured at B/F/TAF initiation was used to evaluate the association between detected resistance and risk of confirmed VR >50 copies/mL (2 consecutive values). FINDINGS: We included 1414 PWH (973-69%-in the VR analysis). Overall, 27% were female, median age was 53 years (IQR 44-59). Major NRTI-DRMs were detected in 25% (95% CI: 22.5, 27.1). Major INSTI-DRMs affecting bictegravir were rare (0.6%, 95% CI: 0.2, 1.4). The overall rate of VR by 36 months was 5.3% (95% CI: 3.7-6.9%), confirming that viral rebound on B/F/TAF is a rare event. After controlling for confounding, NRTI resistance was not associated with VR, whereas a history of INSTI virological failure (VF) and major INSTI-DRMs were associated with VR (aRH 2.68, 95% CI: 1.40, 5.12; and aRH 4.21, 95% CI: 1.18, 15.02, respectively). CONCLUSIONS: In our cohort of PWH who were switched to B/F/TAF, NRTI-DRMs were common, but B/F/TAF remained effective in maintaining viral suppression despite their presence. However, previous failure to INSTI-based regimens and major INSTI-DRMs were risk factors for VR.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Pezzati L, Conti F, Gennari W, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes. J Antimicrob Chemother. 2026. PMID: 41734206. doi:10.1093/jac/dkag035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。